Fibroblast growth factor 21 in heart failure
Open Access
- 27 August 2022
- journal article
- research article
- Published by Springer Nature in Heart Failure Reviews
- Vol. 28 (1) , 261-272
Abstract
Fibroblast growth factor 21 (FGF21) is a peptide hormone involved in energy homeostasis that protects against the development of obesity and diabetes in animal models. Its level is elevated in atherosclerotic cardiovascular diseases (CVD) in humans. However, little is known about the role of FGF21 in heart failure (HF). HF is a major global health problem with a prevalence that is predicted to rise, especially in ageing populations. Despite improved therapies, mortality due to HF remains high, and given its insidious onset, prediction of its development is challenging for physicians. The emergence of cardiac biomarkers to improve prediction, diagnosis, and prognosis of HF has received much attention over the past decade. Recent studies have suggested FGF21 is a promising biomarker candidate for HF. Preclinical research has shown that FGF21 is involved in the pathophysiology of HF through the prevention of oxidative stress, cardiac hypertrophy, and inflammation in cardiomyocytes. However, in the available clinical literature, FGF21 levels appear to be paradoxically raised in HF, potentially implying a FGF21 resistant state as occurs in obesity. Several potential confounding variables complicate the verdict on whether FGF21 is of clinical value as a biomarker. Further research is thus needed to evaluate whether FGF21 has a causal role in HF, and whether circulating FGF21 can be used as a biomarker to improve the prediction, diagnosis, and prognosis of HF. This review draws from preclinical and clinical studies to explore the role of FGF21 in HF.Keywords
Funding Information
- University of New South Wales
- National Heart Foundation of Australia (G 12S 6681, 100715)
- University of New South Wales
This publication has 112 references indexed in Scilit:
- Endocrine Protection of Ischemic Myocardium by FGF21 from the Liver and Adipose TissueScientific Reports, 2013
- Acute Exercise Induces FGF21 Expression in Mice and in Healthy HumansPLOS ONE, 2013
- Endocrine fibroblast growth factors 15/19 and 21: from feast to famineGenes & Development, 2012
- FGF21 regulates PGC-1α and browning of white adipose tissues in adaptive thermogenesisGenes & Development, 2012
- Thermogenic Activation Induces FGF21 Expression and Release in Brown Adipose TissueJournal of Biological Chemistry, 2011
- The cardiokine story unfolds: ischemic stress-induced protein secretion in the heartTrends in Molecular Medicine, 2011
- FGF21 induces PGC-1α and regulates carbohydrate and fatty acid metabolism during the adaptive starvation responseProceedings of the National Academy of Sciences, 2009
- The FGF family: biology, pathophysiology and therapyNature Reviews Drug Discovery, 2009
- Tissue-specific Expression of βKlotho and Fibroblast Growth Factor (FGF) Receptor Isoforms Determines Metabolic Activity of FGF19 and FGF21Journal of Biological Chemistry, 2007
- Endocrine Regulation of the Fasting Response by PPARα-Mediated Induction of Fibroblast Growth Factor 21Cell Metabolism, 2007